Detalhe da pesquisa
1.
Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma.
J Neurooncol
; 146(2): 239-246, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31875307
2.
WINDOW consortium: A path towards increased therapy efficacy against glioblastoma.
Drug Resist Updat
; 40: 17-24, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30439622
3.
The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
BMC Cancer
; 17(1): 204, 2017 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-28320338
4.
The cytosolic ß-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation.
Blood Cells Mol Dis
; 46(1): 19-26, 2011 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20728381
5.
A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities.
Nat Commun
; 11(1): 2935, 2020 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32523045
6.
Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma.
Mol Cancer Ther
; 17(2): 347-354, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28958992
7.
NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor.
Oncotarget
; 6(40): 42717-32, 2015 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26015408
8.
Targeting the Akt-pathway to improve radiosensitivity in glioblastoma.
Curr Pharm Des
; 19(5): 951-7, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-22973963
9.
Human glioma growth is controlled by microRNA-10b.
Cancer Res
; 71(10): 3563-72, 2011 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21471404